Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Authors:

Abstract
MDJ and MTJ contributed equally; FLL and AG contributed equally.IntroductionAxicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are autologous ant